Lysine intake and neurotoxicity in glutaric aciduria type I: Towards a rationale for therapy? [1]

Brain

Volumn 129, Issue 8, 2006, Pages

  Kölker, Stefan ^a   Sauer, Sven W ^a   Okun, Jürgen G ^a   Hoffmann, Georg F ^a   Koeller, David M ^b  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYGLUTARIC ACID; ARGININE; DICARBOXYLIC ACID; GLUTARIC ACID; GLUTARYL COENZYME A DEHYDROGENASE; LEUCINE; LYSINE; ORNITHINE; UNCLASSIFIED DRUG;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE BRAIN DISEASE; BLOOD BRAIN BARRIER; BRAIN DYSFUNCTION; BRAIN EDEMA; BRAIN FUNCTION; BRAIN LEVEL; BRAIN METABOLISM; CELL DAMAGE; DIET RESTRICTION; DIETARY INTAKE; DISEASE MODEL; DISEASE SEVERITY; ENDOTHELIUM CELL; GLUTARIC ACIDURIA TYPE 1; LETTER; MAPLE SYRUP URINE DISEASE; METABOLITE; MOLECULAR DYNAMICS; NERVE CELL; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROPHYLAXIS; SKIN BLOOD VESSEL; SUBARACHNOID HEMORRHAGE; SUPPLEMENTATION; SYNTHESIS; URINARY EXCRETION; URINE LEVEL;

AMINO ACID METABOLISM, INBORN ERRORS; ANIMALS; BRAIN DISEASES, METABOLIC, INBORN; DIET; DISEASE MODELS, ANIMAL; GLUTARATES; LYSINE; MICE;

EID: 33747889120     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awl137     Document Type: Letter

References (21)

1. Baric I, Wagner L, Feyh P, Liesert M, Buckel W, Hoffmann GF. Sensitivity and specificity of free and total glutaric acid and 3-hydroxyglutaric acid measurements by stable-isotope dilution assays for the diagnosis of glutaric aciduria type I. J Inherit Metab Dis 1999; 22: 867-81.
2. Christensen E, Ribes A, Merinero B, Zschocke J. Correlation of genotype and phenotype in glutaryl-CoA dehydrogenase deficiency. J Inherit Metab Dis 2004; 27: 861-8.
3. Funk CBR, Prasad AN, Frosk P, Sauer S, Kölker S, Greenberg CR, et al. Neuropathological, biochemical, and molecular findings in a glutaric acidemia type 1 cohort. Brain 2005; 128: 711-22.
4. Gerstner B, Gratopp A, Marcinkowski M, Sifringer M, Obladen M, Buhrer C. Glutaric acid and its metabolites cause apoptosis in immature oligodendrocytes: a novel mechanism of white matter degeneration in glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2005; 57: 771-6.
5. Goodman SI, Markey SP, Moe PG, Miles BS, Teng CC. Glutaric aciduria: a 'new' disorder of amino acid metabolism. Biochem Med 1975; 12: 12-21.
6. Harris RA, Joshi M, Jeoung NH, Obayashi M. Overview of the molecular and biochemical basis of branched-chain amino acid catabolism. J Nutr 2005; 135: 1527S-30S.
7. Koeller DM, Woontner M, Crnic LS, Kleinschmidt-DeMasters B, Stephens J, Hunt EL, et al. Biochemical, pathologic and behavioral analysis of a mouse model of glutaric acidemia type I. Hum Mol Genet 2002; 11: 347-57.
8. Kölker S, Koeller DM, Okun JG, Hoffmann GF. Pathomechanisms of neurodegeneration in glutaryl-CoA dehydrogenase deficiency. Ann Neurol 2004; 55: 7-12.
9. Kölker S, Garbade SF, Greenberg CR, Leonard JV, Saudubray JM, Ribes A, et al. Natural history, outcome and therapeutic efficacy in children and adults with glutaryl-CoA dehydrogenase deficiency. Pediatr Res 2006; 56: 840-7.
10. Korein J, Sansaricq C, Kalmijn M, Honig J, Lange B. Maple syrup urine disease: clinical, EEG and plasma amino acid correlations with a theoretical mechanism of acute neurotoxicity. Int J Neurosci 1994; 79: 21-45.
11. McMillan TA, Gibson KM, Sweetman L, Meyers GS, Green R. Conservation of central nervous system glutaryl-coenzyme A dehydrogenase in fruit-eating bats with glutaric aciduria and deficient hepatic glutaryl-coenzyme A dehydrogenase. J Biol Chem 1988; 263: 17258-61.
12. Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics 2002; 109: 999-1008.
13. Mühlhausen C, Ott N, Chalajour F, Tilki D, Freudenberg F, Shahhossini M, et al. Endothelial effects of 3-hydroxyglutaric acid: implications of glutaric aciduria type I. Pediatr Res 2006; 59: 196-202.
14. Naughten ER, Mayne PD, Monavari AA, Goodman SI, Sulaiman G, Croke DT. Glutaric aciduria type I: outcome in the Republic of Ireland. J Inherit Metab Dis 2004; 27: 917-20.
15. Sauer SW, Okun JG, Schwab MA, Crnic LR, Hoffmann GF, Goodman SI, et al. Bioenergetics in glutaryl-coenzyme A dehydrogenase deficiency, a role for glutaryl-coenzyme A. J Biol Chem 2005; 280: 21830-6.
16. Sauer SW, Okun JG, Fricker G, Mahringer A, Crnic LR, Mühlhausen C, et al. Intracerebral accumulation of glutaric and 3-hydroxyglutaric acids in glutaryl-coenzyme A dehydrogenase deficiency, a biochemical risk factor for neurodegeneration. J Neurochem 2006; 87: 899-910.
17. Strauss KA, Morton DH. Type I glutaric aciduria, part 2: a model of acute striatal necrosis. Am J Med Genet 2003; 121C: 53-70.
18. Strauss KA, Puffenberger EG, Robinson DL, Morton DH. Type I glutaric aciduria, part 1: natural history of 77 patients. Am JMed Genet 2003; 121C: 38-52.
19. Tamai I, Tsuji A. Transporter-mediated permeation of drugs across the blood-brain barrier. J Pharm Sci 2000; 89: 1371-88.
20. Woontner M, Crnic LS, Koeller DM. Analysis of the expression of murine glutaryl-CoA dehydrogenase: in vitro and in vivo studies.Mol Genet Metab 2000; 69: 116-22.
21. Zinnanti WH, Lazovic J, Wolpert EB, Antonetti DA, Smith MB, Connor JR, et al. A diet-induced mouse model for glutaric aciduria type I. Brain 2006; 129: 899-910.